Psychological impact of 131I radioprotection measures on thyroid cancer patients

Elena Barbus, Claudiu Pestean, Maria Iulia Larg, Katalin Gabora, Eduard-Alexandru Bonci, Claudiu Badulescu, Andra Piciu, Elena Barbus, Claudiu Pestean, Maria Iulia Larg, Katalin Gabora, Eduard-Alexandru Bonci, Claudiu Badulescu, Andra Piciu

Abstract

Background and aims: It is very well know nowadays that despite all the good and qualitative information available, the patients who are supposed to be treated with radioiodine for differentiated thyroid cancer suffer from a lot of concerns prior the treatment. The aim of our study is to investigate the level of anxiety and lessening of the concerns pre and post RIT (radioiodine therapy) using a dedicated, special designed questionnaire.

Methods: A cross-sectional study of 54 differentiated thyroid cancer patients was conducted. Patients who met the inclusion criteria were invited to complete the radioprotection questionnaire pre and post RIT. The questionnaire comprises two sections (pre and post radioiodine treatment) with specific questions regarding aspects of radioprotection measures and the impact on the overall well-being. For uniform distribution of variables we used Pearson correlation and for monotonic relationship between variables, Spearman correlation.

Results: The pre-treatment questionnaire reported a strong confidence of the patients in the medical team, good and accurate information regarding the treatment, >50 % suffering from anxiety and concerns before the radioiodine treatment. The post treatment questionnaire revealed no fear of isolation, a lot of useful information and most of the patients would undergo another treatment, if necessary and also recommend it to others.

Conclusion: The milestone in having a good and compliant patient remains a very good communication between the medical team and the patient. We are able to influence and change things and have fewer patients with fear from radioactivity and treatment concerns if we dedicate enough time to give them the adequate information in the best way so it will be correctly received.

Keywords: iodine radioisotopes; radioactivity; surveys and questionnaires; thyroid neoplasms.

Figures

Figure 1
Figure 1
Correlation between isolation during the treatment and fear regarding the presentation in the nuclear medicine department.
Figure 2
Figure 2
Correlation between isolation during the treatment and fear of the treatment (radioiodine therapy).

References

    1. Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997;7(2):163–176.
    1. Piciu D. Thyroid cancer incidence 25 years after Chernobyl, in a Romanian cancer center: is it a public health problem? Curr Radiopharm. 2013;6(4):249–252.
    1. Piciu D, Irimie A, Piciu A. Investigation of thyroid carcinoma over 40 years, using the database of the Ion Chiricuta Institute of Oncology Cluj-Napoca. J BUON. 2014;19(2):524–529.
    1. Quimby EH. The fear of radiation. Am Assoc Ind Nurses J. 1967;15(3):19.
    1. Pastel RH, Mulvaney J. Fear of radiation in U.S. military medical personnel. Mil Med. 2001;166(12 Suppl):80–82.
    1. Bhat M. “Fear of radiation” is frightening. Australas Phys Eng Sci Med. 2010;33(3):215–217.
    1. Beauchamp RC. Radiation, Fear, and Common Sense Adaptations in Patient Care. Nurs Clin North Am. 2016;51(4):675–695.
    1. Wang B, Katsube T, Begum N, Nenoi M. Revisiting the health effects of psychological stress-its influence on susceptibility to ionizing radiation: a mini-review. J Radiat Res. 2016;57(4):325–335.
    1. Bãrbuş E, Peştean C, Larg MI, Piciu D. Quality of life in thyroid cancer patients: a literature review. Clujul Med. 2017;90(2):147–153.
    1. Rosenthal MS. Patient misconceptions and ethical challenges in radioactive iodine scanning and therapy. J Nucl Med Technol. 2006;34(3):143–150. quiz 151–152.
    1. von Müller F, Happel C, Reinhardt J, Kranert WT, Bockisch B, Gröner D, et al. Evaluation of fear of radiation and isolation before and after radioiodine therapy. Thyroid. 2014;24(7):1151–1155.
    1. Sherry I. Nuclear medicine: will I glow in the dark, nurse? Nurs Stand. 2000;14(19):48–53.
    1. D’haese S, Vinh-Hung V, Bijdekerke P, Spinnoy M, De Beukeleer M, Lochie N, et al. The effect of timing of the provision of information on anxiety and satisfaction of cancer patients receiving radiotherapy. J Cancer Educ. 2000;15(4):223–227.
    1. Freudenberg LS, Beyer T, Müller SP, Görges R, Hopfenbach A, Bockisch A. Evil radioactivity. Subjective perception of radioactivity in patients with thyroid disease prior to treatment with radioiodine. Nuklearmedizin. 2006;45(5):229–234.
    1. Piciu D, Pestean C, Barbus E, Larg MI, Piciu A. Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131. Clujul Med. 2016;89(3):384–389.
    1. Gillan C, Abrams D, Harnett N, Wiljer D, Catton P. Fears and misperceptions of radiation therapy: sources and impact on decision-making and anxiety. J Cancer Educ. 2014;29(2):289–295.
    1. Banach R, Bartès B, Farnell K, Rimmele H, Shey J, Singer S, et al. Results of the Thyroid Cancer Alliance international patient/survivor survey: Psychosocial/informational support needs, treatment side effects and international differences in care. Hormones (Athens) 2013;12(3):428–438.
    1. Tagay S, Herpertz S, Langkafel M, Erim Y, Bockisch A, Senf W, et al. Health-related Quality of Life, depression and anxiety in thyroid cancer patients. Qual Life Res. 2006;15(4):695–703.
    1. Taïeb D, Baumstarck-Barrau K, Sebag F, Fortanier C, De Micco C, Loundou A, et al. Heath-related quality of life in thyroid cancer patients following radioiodine ablation. Health Qual Life Outcomes. 2011 May 13;9:33. doi: 10.1186/1477-7525-9-33.
    1. Domènech A, Notta P, Benítez A, Ramal D, Rodríguez-Bel L, Massuet C, et al. Evaluation of the anxiety state in patients receiving radioiodine treatment or who undergo a sentinel lymph node examination in the Nuclear Medicine Department. Rev Esp Med Nucl. 2010;29(2):63–72.
    1. Fischhoff B, Slovic P, Lichtenstein S, Read S, Combs B. Policy Sci. 2. Vol. 9. Kluwer Academic Publishers; 1978. Apr, How safe is safe enough? A psychometric study of attitudes towards technological risks and benefits; pp. 127–152. Available from: .
    1. Taïeb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf) 2009;71(1):115–123.
    1. Piciu A, Piciu D, Marlowe RJ, Irimie A. Highly-sensitive C-reactive protein, a biomarker of cardiovascular disease risk, in radically-treated differentiated thyroid carcinoma patients after repeated thyroid hormone withholding. Exp Clin Endocrinol Diabetes. 2013;121(2):102–108.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться